Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KILL QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

By: Business Wire

 

QurAlis Corporation requests that their press release NewsItemId: 20260224184980 “QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS” be killed. 

The release will be re-issued on Feb. 24, 2026.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.18
-5.93 (-2.82%)
AAPL  267.70
+3.12 (1.18%)
AMD  195.47
-4.68 (-2.34%)
BAC  51.40
-1.66 (-3.14%)
GOOG  312.93
-1.97 (-0.63%)
META  639.42
-16.24 (-2.48%)
MSFT  386.35
-10.88 (-2.74%)
NVDA  190.77
+0.95 (0.50%)
ORCL  140.00
-8.08 (-5.46%)
TSLA  394.79
-17.03 (-4.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.